Emergent Biosolutions (EBS)

$10.93 -0.06 (-0.55%)
Market Cap 574.04M
Revenue (ttm) 1.04B
Net Income (ttm) -190.60M
EPS (ttm) N/A
PE Ratio 5.55
Forward PE N/A
Profit Margin -18.26%
Debt to Equity Ratio 1.14
Volume 567,500
Avg Vol 797,530
Day's Range N/A - N/A
Shares Out 52.52M
Stochastic %K 48%
Beta 2.35
Analysts Strong Sell
Price Target $13.50

Company Profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax va...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 240 631 3200
Address:
300 Professional Drive, Gaithersburg, United States
BavarianStallion
BavarianStallion Feb. 23 at 3:42 PM
$EBS thats how the mangement should act
1 · Reply
ComradeKomisar
ComradeKomisar Feb. 23 at 2:09 PM
$EBS If you find that other 'opportunit-ay', make sure it is profitable.
1 · Reply
Estimize
Estimize Feb. 23 at 2:01 PM
Wall St is expecting 0.11 EPS for $EBS Q4 [Reporting 02/26 AMC] http://www.estimize.com/intro/ebs?chart=historical&metric_name=eps&utm_cont
0 · Reply
ComradeKomisar
ComradeKomisar Feb. 23 at 12:59 PM
$EBS About that 'opportunitay kawst' of being here. Sure hope you ain't going to go ...over there.
1 · Reply
billywilliamz
billywilliamz Feb. 23 at 11:20 AM
$EBS where
0 · Reply
Hi_there
Hi_there Feb. 23 at 11:10 AM
$EBS why we trending?
0 · Reply
BavarianStallion
BavarianStallion Feb. 23 at 10:09 AM
I dreamed that night that we end there this week
0 · Reply
DragonAlgo
DragonAlgo Feb. 23 at 10:06 AM
🐉 $EBS CALL — DragonAlgo® Signal Contract: EBS CALL Expiry: 2026-03-20 | Strike: $13.00 | Type: CALL Option Plan (premium): Entry: $0.68 Stop: $0.49 TP1: $0.88 TP2: $1.16 TP3: $1.63 🔗 https://dragonalgo.com
0 · Reply
billywilliamz
billywilliamz Feb. 22 at 9:40 PM
$EBS where ??? How much
0 · Reply
ImmxBeliever
ImmxBeliever Feb. 22 at 7:53 PM
$EBS
0 · Reply
Latest News on EBS
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

Feb 12, 2026, 6:00 PM EST - 10 days ago

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Feb 12, 2026, 9:02 AM EST - 11 days ago

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading

Jan 15, 2026, 1:08 PM EST - 5 weeks ago

NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading

Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 11:55 PM EST - 5 weeks ago

Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

Jan 12, 2026, 7:30 AM EST - 6 weeks ago

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

Jan 8, 2026, 4:30 PM EST - 6 weeks ago

Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

Jan 8, 2026, 8:00 AM EST - 6 weeks ago

Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Jan 7, 2026, 7:59 AM EST - 6 weeks ago

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

Dec 12, 2025, 8:30 AM EST - 2 months ago

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

Nov 18, 2025, 8:00 AM EST - 3 months ago

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

Nov 12, 2025, 4:01 PM EST - 3 months ago

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

Emergent BioSolutions: Solid Q3, Expecting Better Days To Come

Nov 6, 2025, 11:00 PM EST - 3 months ago

Emergent BioSolutions: Solid Q3, Expecting Better Days To Come

Emergent BioSolutions Inc. (EBS) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 8:56 PM EDT - 4 months ago

Emergent BioSolutions Inc. (EBS) Q3 2025 Earnings Call Transcript

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Oct 29, 2025, 4:15 PM EDT - 4 months ago

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

Oct 28, 2025, 8:00 AM EDT - 4 months ago

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

Oct 8, 2025, 7:45 AM EDT - 4 months ago

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

Sep 24, 2025, 4:05 PM EDT - 5 months ago

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

Sep 19, 2025, 8:34 AM EDT - 5 months ago

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

Sep 15, 2025, 8:35 AM EDT - 5 months ago

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Sep 9, 2025, 7:30 AM EDT - 5 months ago

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Sep 2, 2025, 7:40 AM EDT - 6 months ago

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Aug 29, 2025, 8:05 AM EDT - 6 months ago

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Aug 27, 2025, 8:01 AM EDT - 6 months ago

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

Aug 21, 2025, 8:45 AM EDT - 6 months ago

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally

Aug 12, 2025, 12:46 PM EDT - 6 months ago

Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally

Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:31 PM EDT - 7 months ago

Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:15 PM EDT - 7 months ago

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

Jul 28, 2025, 8:50 AM EDT - 7 months ago

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Jul 28, 2025, 8:50 AM EDT - 7 months ago

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 15, 2025, 7:30 AM EDT - 7 months ago

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

Jul 8, 2025, 4:45 PM EDT - 8 months ago

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

Jul 2, 2025, 4:05 PM EDT - 8 months ago

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

Jun 23, 2025, 8:05 AM EDT - 8 months ago

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful

Jun 20, 2025, 2:25 PM EDT - 8 months ago

Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful

Emergent BioSolutions Announces Addition to Russell 3000® Index

Jun 20, 2025, 8:13 AM EDT - 8 months ago

Emergent BioSolutions Announces Addition to Russell 3000® Index

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

Jun 5, 2025, 7:00 AM EDT - 9 months ago

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript

May 7, 2025, 10:01 PM EDT - 10 months ago

Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript

Emergent BioSolutions Reports First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 10 months ago

Emergent BioSolutions Reports First Quarter 2025 Financial Results

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

May 1, 2025, 5:07 PM EDT - 10 months ago

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

Apr 22, 2025, 8:00 AM EDT - 10 months ago

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

Emergent BioSolutions Announces Stock Repurchase Program

Mar 31, 2025, 8:00 AM EDT - 11 months ago

Emergent BioSolutions Announces Stock Repurchase Program

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

Mar 20, 2025, 4:30 PM EDT - 1 year ago

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

Mar 20, 2025, 8:06 AM EDT - 1 year ago

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

Mar 13, 2025, 8:29 AM EDT - 1 year ago

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Mar 10, 2025, 9:14 AM EDT - 1 year ago

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 7:58 PM EST - 1 year ago

Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call Transcript

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:23 PM EST - 1 year ago

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

BavarianStallion
BavarianStallion Feb. 23 at 3:42 PM
$EBS thats how the mangement should act
1 · Reply
ComradeKomisar
ComradeKomisar Feb. 23 at 2:09 PM
$EBS If you find that other 'opportunit-ay', make sure it is profitable.
1 · Reply
Estimize
Estimize Feb. 23 at 2:01 PM
Wall St is expecting 0.11 EPS for $EBS Q4 [Reporting 02/26 AMC] http://www.estimize.com/intro/ebs?chart=historical&metric_name=eps&utm_cont
0 · Reply
ComradeKomisar
ComradeKomisar Feb. 23 at 12:59 PM
$EBS About that 'opportunitay kawst' of being here. Sure hope you ain't going to go ...over there.
1 · Reply
billywilliamz
billywilliamz Feb. 23 at 11:20 AM
$EBS where
0 · Reply
Hi_there
Hi_there Feb. 23 at 11:10 AM
$EBS why we trending?
0 · Reply
BavarianStallion
BavarianStallion Feb. 23 at 10:09 AM
I dreamed that night that we end there this week
0 · Reply
DragonAlgo
DragonAlgo Feb. 23 at 10:06 AM
🐉 $EBS CALL — DragonAlgo® Signal Contract: EBS CALL Expiry: 2026-03-20 | Strike: $13.00 | Type: CALL Option Plan (premium): Entry: $0.68 Stop: $0.49 TP1: $0.88 TP2: $1.16 TP3: $1.63 🔗 https://dragonalgo.com
0 · Reply
billywilliamz
billywilliamz Feb. 22 at 9:40 PM
$EBS where ??? How much
0 · Reply
ImmxBeliever
ImmxBeliever Feb. 22 at 7:53 PM
$EBS
0 · Reply
alwayzwong
alwayzwong Feb. 22 at 7:24 PM
$EBS
0 · Reply
Kawasaki1
Kawasaki1 Feb. 22 at 6:37 PM
$EBS Big Ole' God candle just after the close 🤑🤔
0 · Reply
alwayzwong
alwayzwong Feb. 22 at 6:25 PM
$EBS the stonk hasnt done chit in 3 years….. fux
0 · Reply
billywilliamz
billywilliamz Feb. 21 at 3:29 PM
$EBS 20$ ask.
1 · Reply
alwayzwong
alwayzwong Feb. 21 at 1:35 AM
$EBS
0 · Reply
Hi_there
Hi_there Feb. 20 at 10:29 PM
$EBS if this bitch hits 40 I buy the new Audi RS5
1 · Reply
billywilliamz
billywilliamz Feb. 20 at 9:35 PM
$EBS booooring opex….
0 · Reply
ImmxBeliever
ImmxBeliever Feb. 20 at 8:06 PM
$EBS When bOOlish
0 · Reply
billywilliamz
billywilliamz Feb. 20 at 6:17 PM
$EBS oh siii
0 · Reply
NRG8
NRG8 Feb. 20 at 5:57 PM
$EBS Added a few more $EBS today. Have a great weekend! .
0 · Reply
alwayzwong
alwayzwong Feb. 20 at 5:35 PM
$EBS si señor
1 · Reply
ComradeKomisar
ComradeKomisar Feb. 20 at 4:20 PM
$EBS Technically, we're fine.
1 · Reply